Related Experiment Video

Updated: Jul 21, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Poly(ADP-ribosylation) processing as a target for the anti-tumor effects of the cell differentiating agent,

T Alderson1

  • 1Department of Pharmacology, Cambridge University, UK.

Anti-Cancer Drugs
|December 1, 1991
PubMed

Insights

Poly(ADP-ribosylation) is a key cellular process targeted in cancer chemotherapy. This study explores its role in anti-tumor effects and proposes new therapeutic strategies involving N6-substituted adenosines.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Poly(ADP-ribosylation) is a crucial post-translational modification of nuclear proteins.
  • This process is implicated in DNA repair, gene expression, and cell death.
  • Dysregulation of poly(ADP-ribosylation) is observed in various cancers.

Purpose of the Study:

  • To elucidate the role of poly(ADP-ribosylation) in cancer chemotherapy.
  • To investigate the anti-tumor mechanisms of hexamethylenebisacetamide, a cell differentiating agent.
  • To explore novel pharmacological approaches for tumor therapy.

Main Methods:

  • Review of cellular processes regulating poly(ADP-ribosylation).
  • Analysis of the effects of hexamethylenebisacetamide on tumor cells.
  • Consideration of N6-substituted adenosines as potential anti-tumor agents.

Main Results:

  • Poly(ADP-ribosylation) is a significant target for cancer chemotherapy.
  • Hexamethylenebisacetamide exhibits anti-tumor effects through mechanisms involving poly(ADP-ribosylation).
  • Oncogene activation influences tumor cell response to therapies targeting poly(ADP-ribosylation).

Conclusions:

  • Poly(ADP-ribosylation) modulation offers a promising strategy for cancer treatment.
  • N6-substituted adenosines show potential for tumor therapy by affecting poly(ADP-ribosylation) and other cellular pathways.
  • Targeting poly(ADP-ribosylation) in conjunction with oncogene status may enhance therapeutic efficacy.

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells06:53

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells

Published on: June 2, 2022

Related Concept Videos

RNA Editing02:23

RNA Editing

RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...